Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic

Journal of Clinical Psychopharmacology

Volumn 19, Issue 3, 1999, Pages 209-221

  Ramaekers, J G ^a   Louwerens, J W ^a   Muntjewerff, N D ^a   Milius, H ^a   De Bie, A ^a   Rosenzweig, P ^b   Patat, A ^b   O'Hanlon, J F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; HALOPERIDOL; PLACEBO;

ADULT; AFFECTIVE NEUROSIS; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR BINDING; WELLBEING;

ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; PSYCHOMOTOR PERFORMANCE; SULPIRIDE;

EID: 0032927133     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199906000-00003     Document Type: Article

References (44)

1. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10[suppl 3]:105-14.
2. King DJ. Measures of neuroleptic effects on cognition and psychomotor performance in healthy volunteers. In: Hindmarch I, Stonier PD, eds. Human psychopharmacology, vol 4. West Sussex: John Wiley & Sons Ltd., 1993:195-203.
3. Levander T. Neuroleptics and the neuroleptic deficit syndrome. Acta Psychiatr Scand 1994;89[suppl 380]:8-13.
4. Lader M. Old problem, new challenge. J Psychopharmacol 1993; 7:392-3
5. King DJ. Psychomotor disturbances induced by neuroleptics. Acta Psychiatr Scand 1994;89[suppl 380]:53-9.
6. Baldessarini R, Frankenburg FR. Clozapine, a novel antipsychotic agent. N Engl J Med 1991;324:746-54.
7. Meltzer HY. Atypical antipsychotics. In: Bloom FE, Kupher DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1994:1277-86.
8. Leysen JE, Gommeren W, Schotte A. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In: Kane JM, Möller HJ, Wouters FA, eds. Serotonin antipsychotic treatment. New York: Marcel Dekker, 1996:51-75.
9. Freeman HL. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol 1997;12[suppl 2]:11-8.
10. Rein W, Turjanski S. Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 1997,12[suppl 2]:19-36.
11. Kahn JP, Laxenaire M, Burnat G, Albaret C, Holm AC. Remoxipride in acute psychosis: intramuscular followed by oral treatment compared to haloperidol, a double blind, multicenter trial. Hum Psychopharmacol 1994;9:79-92.
12. Liljequist R, Linnoila M, Mattila MJ, Saario I, Seppälä T. Effects of two weeks' treatment with thioridazine, chlorpromazine, sulpiride and bromazepam, alone or in combination with alcohol, on learning and memory in man. Psychopharmacologia 1975;44: 205-8.
13. Bartfai A, Wiesel FA. Effects of sulpiride on vigilance in healthy subjects. Int J Psychophysiol 1986;4:1-5.
14. Fagan D, Scott DB, Mitchell M, Tiplady B. Effects of remoxipride on measures of psychological performance in healthy volunteers. Psychopharmacology (Berl) 1991;105:225-9.
15. Mattila MJ, Mattila ME, Konno K, Saariolho-Kere U. Objective and subjective effects of remoxipride, alone and in combination with ethanol or diazepam, on performance in healthy subjects. J Psychopharmacol 1988;2:138-49.
16. McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 1990;30: 795-803.
17. King DJ, Best P, Lynch G, Mannion MF, Montgomery RC, Tiplady B, Yisak W. The effects of remoxipride and chlorpromazine on eye movements and psychomotor performance in healthy volunteers. J Psychopharmacol 1995;2:143-50.
18. Rammsayer T, Gallhofer V. Remoxipride versus haloperidol in healthy volunteers: psychometric performance and subjective tolerance profiles. Int Clin Psychopharmacol 1995;10:31-7.
19. Mattila MJ, Patat A, Seppälä T, Kalska H, Jalava ML, Vanakoski J, Lavanant C. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. Eur J Clin Pharmacol 1996;51:161-6.
20. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83-97.
21. 3 dopamine receptor antagonistic activity and limbic selectivity. J Pharmacol Exp Ther 1997;280: 73-82.
22. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H. Amisulpride from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997;12[suppl 2]: 29-36.
23. King DJ. BAP consensus statement: guidelines for the use of antipsychotic drug studies in healthy volunteers. J Psychopharmacol 1997;11:201-10.
24. King DJ, Burke M, Lucas RA. Antipsychotic drug-induced dysphoria. Br J Psychiatry 1995;167:480-2.
25. Anderson BG, Reker D, Cooper T. Prolonged adverse effects of haloperidol in normal subjects. N Engl J Med 1981;305:643-4.
26. Froemming JS, Francis Lam YW, Jann MW, Davis CM. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989;17:396-423.
27. Coukell AJ, Spencer CM, Benfield P. Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996;6:237-56.
28. Jex HR, McDonnell JD, Phatak AV. Critical tracking task for manual control research, IEEE Trans Hum Fac Electron 1966;7:138-45.
29. Moskowitz H. laboratory studies on the effects of alcohol on some variables related to driving. Saf Res 1973;5:185-99.
30. Mackworth NH. Researches on the measurement of human performance. Medical Research Council special report no. 268. London: H.M. Stationary Office, 1950.
31. Baddeley AD. A three-minute test based on grammatical transformation. Psychometr Sci 1968;72:257-69.
32. Wechsler D. The measurement and appraisal of adult intelligence. Baltimore: Williams & Wilkins, 1981.
33. Simpson GM, Angus JWS. Drug-induced extrapyramidal disorders: a rating scale for extrapyramidal effects. Acta Psychiatr Scand Suppl 1970;212:11-9.
34. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
35. Haertzen CA. Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep 1966;18:163-94.
36. Kay SR. Positive and negative symptoms in schizophrenia. New York: Brunner Mazel, 1991.
37. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1976;6:278-96.
38. Naber D, Walther A, Kircher T, Hayek R, Holzbach R. Subjective effects of neuroleptics predict compliance. In: Gaebel W, Awad R, eds. Prediction of neuroleptic treatment outcome in schizophrenia - concepts and methods. Heidelberg: Springer, 1994:85-98.
39. Wing JK, Sturp E. The PSE-IDEE CATEGO system supplementary manual. London: Institute of Psychiatry, 1978.
40. Wing JK, Cooper J, Sartorius N. The Measurement and classification of psychiatric symptoms. Cambridge: Cambridge University Press, 1974.
41. Peretti CS, Danion JM, Kauffmann-Muller F, Grange D, Patat A, Rosenzweig P. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology (Berl) 1997;131:329-38.
42. Grünberger J, Saletu B, Linzmayer L, Stöhr H. Determination of pharmacokinetics and pharmacodynamics of amisulpride by pharmaco-EEG and psychometry. In: Pichot P, Berner P, Wolf R, Thau, eds. Psychiatry: the state of the art. New York: Plenum Press, 1985:681-6.
43. Le Moal M. Mesocorticolimbic dopaminergic neurons: functional and regulatory rules. In: Bloom FE, Kupher DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1994:283-94.
44. Van Putten T, Marder SR, Mintz I, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;49:500-5.